UBS analyst Kevin Caliendo maintains $Owens & Minor (OMI.US)$ with a buy rating, and adjusts the target price from $28 to $25.
According to TipRanks data, the analyst has a success rate of 54.7% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Owens & Minor (OMI.US)$'s main analysts recently are as follows:
Owens & Minor's Q3 results presented a combination of expectations and variability, with revenues aligning with projections but segment profitability showing inconsistency. The company is actively addressing its eligibility backlog, which stems from the Change hack incident.
The company's third-quarter performance, which surpassed expectations, was counterbalanced by a reduction in the profitability outlook for fiscal year 2024 alongside concerns regarding negative free cash flow.
The company experienced a mixed quarter, with notable EBIT growth in the Patient Direct segment contrasting with weaker performance in Product & Health Services. The standout for the quarter was the robust operating margin observed in Patient Direct. However, there is a growing concern regarding margin pressure in medical distribution, which raises further questions about competitive movements within the industry and brings about a more cautious stance on the outlook for margin progression leading into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士銀行分析師Kevin Caliendo維持$歐麥斯-麥能醫療 (OMI.US)$買入評級，並將目標價從28美元下調至25美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.7%，總平均回報率為4.4%。
此外，綜合報道，$歐麥斯-麥能醫療 (OMI.US)$近期主要分析師觀點如下：
Owens＆Minor的第三季度業績呈現出期望和變化並存的組合，收入與預期一致，但業務板塊的盈利能力表現不穩定。公司正在積極解決其資格積壓問題，這是由於Change黑客事件引起的。
公司第三季度的表現超出了預期，但與此同時，2024財政年度盈利前景下調，同時對負自由現金流出現擔憂。
公司經歷了一個複雜的季度，在Patient Direct板塊的明顯EBIt增長與Product＆Health Services的業績疲軟相對應。該季度的亮點是Patient Direct觀察到的強勁營業利潤率。然而，對醫療分配的利潤率壓力日益加劇，這引發了關於行業內競爭動向的更多疑慮，並對2025年的利潤率進展前景採取更加謹慎的態度。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
